Q4 2024 KP Tissue Inc Earnings Call Transcript
Key Points
- KP Tissue Inc (KPTSF) reported record revenue of over $2 billion for fiscal 2024, with strong adjusted EBITDA in all four quarters.
- The company achieved double-digit revenue growth year-over-year in Q4 2024, driven by higher sales volume in the US and favorable selling prices in Canada.
- Adjusted EBITDA improved by 9.2% year-over-year to $66.8 million in Q4 2024, supported by higher sales volume and increased selling prices.
- The successful start-up of new production assets, including a paper machine and facial tissue line at Sherbrooke, exceeded production targets.
- KP Tissue Inc (KPTSF) continued to invest in its 'Made in Canada' positioning, leveraging consumer patriotism and achieving marketing excellence with several industry awards.
- The company reported a net loss of $13.7 million in Q4 2024, compared to a net income of $16.5 million in Q4 2023, due to higher foreign exchange losses and increased depreciation and interest expenses.
- Higher pulp prices and additional outsourcing activities partially offset the gains in adjusted EBITDA.
- The Away-From-Home segment experienced a decrease in sales volumes year-over-year and sequentially in Q4 2024, impacting order fulfillment.
- The company faces potential tariff exposure, with approximately one-third of its revenue at risk due to finished goods tariffs from Canada to the US.
- KP Tissue Inc (KPTSF) is cautious about the evolving North American trade environment, which could impact future business operations and delay major projects like the new TAD paper machine.
Good morning, and welcome to KP Tissue's fourth quarter 2024 results conference Call. Today's call is being recorded for replay. (Operator Instructions) I will now turn over to Doris Grbic, Director of Investor Relations. You may begin your conference.
Thank you, operator. Good morning, everyone, and thank you for joining us to review Kruger Products fourth quarter 2024 financial results.
With me this morning is Dino Bianco, the CEO of KP Tissue and Kruger Products; and Michael Keays, the CFO of KP Tissue and Kruger Products. Today's discussion will include certain forward-looking statements. Actual results could differ materially from these forward-looking statements due to known and unknown risks and uncertainties. A list of risk factors can be found in our public filings.
In addition, today's discussion will include certain non-GAAP financial measures. The reconciliation of these non-GAAP financial measures to the most comparable GAAP measure can be found in our MD&A. The press
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
